Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment (HYGIA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00741585 |
|
Recruitment Status :
Completed
First Posted : August 26, 2008
Last Update Posted : August 28, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The HYGIA study was designed to investigate prospectively
- the prognostic value of ambulatory blood pressure (BP) monitoring among subjects primarily evaluated at primary care settings
- the impact of changes in ambulatory BP during follow-up in cardiovascular, cerebrovascular, metabolic, and renal risk in hypertensive patients
- the influence of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk in hypertensive patients
- the prevalence of an altered BP profile as a function of antihypertensive treatment, circadian time of treatment, age, and presence of diabetes, among other factors.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Essential Hypertension Cardiovascular Disease Stroke Chronic Kidney Disease | Drug: Any antihypertensive medication alone or in combination Device: Ambulatory blood pressure monitoring | Phase 4 |
Ambulatory blood pressure (BP) measurements (ABPM) correlate more closely with target organ damage and cardiovascular events than clinical cuff measurements. ABPM reveals the significant circadian variation in BP, which in most individuals presents a morning increase, small post-prandial decline, and more extensive lowering during nocturnal rest. However, under certain pathophysiological conditions, the nocturnal BP decline may be reduced (non-dipper pattern) or even reversed (riser pattern). This is clinically relevant since the non-dipper and riser circadian BP patterns constitute a risk factor for left ventricular hypertrophy, albuminuria, cerebrovascular disease, congestive heart failure, vascular dementia, and myocardial infarction. Hence, there is growing interest in how to best tailor and individualize the treatment of hypertension according to the specific circadian BP pattern of each patient.
The reduction of the normal 10-20% sleep-time BP decline that is characteristic of the non-dipper and riser patterns is indeed associated with elevated risk of target organ damage, particularly to the heart (left ventricular hypertrophy, congestive heart failure, and myocardial infarction), brain (stroke), and kidney (albuminuria and progression to end-stage renal failure). These results suggest that cardiovascular risk could be influenced not by BP elevation alone, but also by the magnitude of the circadian BP variability. However, the potential dimension of an altered BP profile is still under debate, as there is current discrepancy on the actual prevalence of a non-dipper BP profile among groups of interest, mainly the elderly, patients with diabetes and patients with resistant hypertension.
Moreover, several independent prospective studies have suggested that nighttime BP may be a better predictor of cardiovascular risk than daytime BP. Common to all previous trials is that prognostic significance of ABPM has relied on a single baseline profile from each participant, without accounting for possible changes in the BP pattern, mainly associated to antihypertensive therapy and aging during follow-up. Moreover, the potential benefit, i.e., reduction in cardiovascular risk, associated with the normalization of the circadian BP variability (e.g., conversion from non-dipper to dipper pattern) from appropriately envisioned treatment strategy is still a matter of debate.
The HYGIA study was designed to investigate, first, the comparative prognostic value of several BP parameters (including, among many others, BP variability, the diurnal/nocturnal ratio, diurnal and nocturnal means, hyperbaric index, slope of morning rise, etc) in the prediction of vascular, metabolic, and renal morbidity and mortality; second, whether potential changes in the circadian BP pattern after treatment with hypertension medications may be associated to changes in the risk of cardiovascular events, stroke, diabetes, and/or chronic kidney disease; and third, in keeping with the second major objective above, to further assess the potential changes in efficacy, safety profile, and/or capability of hypertension medications, used either alone or in combination, to modulate the circadian BP pattern and to reduce vascular, metabolic, and renal risks as a function of the circadian time of administration.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 21983 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment |
| Actual Study Start Date : | September 1, 2008 |
| Actual Primary Completion Date : | June 30, 2018 |
| Actual Study Completion Date : | June 30, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: 1
Treatment with all prescribed hypertension medications on awakening
|
Drug: Any antihypertensive medication alone or in combination
All drugs on awakening
Other Names:
Device: Ambulatory blood pressure monitoring Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours
Other Name: ABPM |
|
Active Comparator: 2
Treatment with at least one prescribed hypertension medication at bedtime
|
Drug: Any antihypertensive medication alone or in combination
One or more drugs at bedtime
Other Names:
Device: Ambulatory blood pressure monitoring Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours
Other Name: ABPM |
- To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk assessment. [ Time Frame: Yearly evaluation for at least ten years ]
- To evaluate the influence of circadian time of treatment in BP control of hypertensive patients. [ Time Frame: Yearly evaluation for at least ten years ]
- To evaluate the prevalence of an altered (non-dipper) BP profile in patients with resistant hypertension as a function of the circadian time of treatment. [ Time Frame: Yearly evaluation for at least ten years ]
- To evaluate the influence of diabetes and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile. [ Time Frame: Yearly evaluation for at least ten years ]
- To evaluate the influence of age and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile. [ Time Frame: Yearly evaluation for at least ten years ]
- To evaluate, for all groups of interest, the prevalence and vascular, metabolic, and renal risk profile of white-coat hypertension. [ Time Frame: Yearly evaluation for at least ten years ]
- To evaluate, for all groups of interest, the prevalence and vascular, metabolic, and renal risk profile of masked hypertension. [ Time Frame: Yearly evaluation for at least ten years ]
- To evaluate, for all previous objectives, potential differences between men and women. [ Time Frame: Yearly evaluation for at least ten years ]
- To evaluate the impact of changes in ambulatory BP in vascular, metabolic, and renal risk assessment. [ Time Frame: Yearly evaluation for at least ten years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Male or female subjects ≥18 years of age.
- High-normal BP or essential hypertension.
- Any subject with recommendation for evaluation with ABPM according to the 2007 European Guidelines.
- Informed consent to participate in the study prior to any study procedures.
Exclusion Criteria:
- Known or suspected contraindications to any potential medication under investigation.
- Shift-workers.
- Inability to communicate and comply with all study requirements.
- Persons directly involved in the execution of this protocol.
- Intolerants to the use of the ABPM device.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00741585
Show 20 study locations
| Study Director: | Ramon C Hermida, PhD | University of Vigo |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Ramon C. Hermida, Professor, University of Vigo |
| ClinicalTrials.gov Identifier: | NCT00741585 |
| Other Study ID Numbers: |
HYGIA Hygia-2007-440 |
| First Posted: | August 26, 2008 Key Record Dates |
| Last Update Posted: | August 28, 2018 |
| Last Verified: | August 2018 |
|
Ambulatory blood pressure monitoring Chronotherapy Circadian Non-dipper |
Type 2 diabetes Resistant hypertension Total mortality |
|
Kidney Diseases Renal Insufficiency, Chronic Cardiovascular Diseases Vascular Diseases Urologic Diseases Renal Insufficiency Quinapril Hypertension Essential Hypertension Atenolol Amlodipine Valsartan Telmisartan Carvedilol Candesartan |
Candesartan cilexetil Ramipril Olmesartan Olmesartan Medoxomil Enalapril Enalaprilat Lisinopril Irbesartan Antihypertensive Agents Lercanidipine Manidipine Doxazosin Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |